Cancers | Free Full-Text | Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors | Clinical Epigenetics | Full Text
Tazemetostat in R/R FL: Original Trial Data and a Propensity Score-Matched Analysis
Histone-writer cancer drugs enter center stage | Nature Biotechnology
Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma
Buy Tazverik (tazemetostat) Online • Price & Costs | Everyone.org
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology
Known EZH2 inhibitors. GSK126, tazemetostat and CPI-1205 are in... | Download Scientific Diagram
Epigenetic targets are a rich vein of innovative drugs
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study - The Lancet Oncology
Tazemetostat: First Approval | SpringerLink
Additional data from Phase 1 study of tazemetostat announced
Tazverik (tazemetostat) for the Treatment of Epithelioid Sarcoma
ESMO 2021: Safety of Tazemetostat in Combination With Abiraterone/Prednisone or Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma | Business Wire
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study - The Lancet Oncology
OncLive.com on Twitter: "Watch our upcoming live broadcast reviewing a new indication, clinical trial data, and dosing for TAZVERIK TM (tazemetostat): https://t.co/YKnSN20tj9 https://t.co/ZfU6XQc4Gd" / Twitter
Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program | Business Wire
The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B‐cell lymphoma and enhances T‐cell recruitment - Yuan - 2021 - Cancer Science - Wiley Online Library
Tazemetostat - Wikipedia
FDA Approves Tazemetostat for Advanced Epithelioid Sarcoma | ONS Voice
Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer | Journal of Medicinal Chemistry
Tazemetostat - an overview | ScienceDirect Topics
tazemetostat | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
